Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	13.06B +162.7%
Revenue (ttm)	944.00M +33.9%
Net Income	-381.00M
EPS	-2.38
Shares Out	161.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,185,716
Open	80.32
Previous Close	80.93
Day's Range	78.92 - 82.44
52-Week Range	23.95 - 86.74
Beta	0.31
Analysts	Strong Buy
Price Target	85.14 (+5.62%)
Earnings Date	Feb 25, 2026

About IONS

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 1,069
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS
• Website: https://www.ionis.com

Financial Performance

In 2025, Ionis Pharmaceuticals's revenue was $944.00 million, an increase of 33.87% compared to the previous year's $705.14 million. Losses were -$381.00 million, -16.06% less than in 2024.

Analyst Summary

According to 22 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $85.14, which is an increase of 5.62% from the latest price.

Price Target

$85.14

(5.62% upside)

Analyst Consensus: Strong Buy